Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Uveitis in leprosy patients]

M Namisato1, K Morii, S Asami

  • 1National Leprosarium Tama-Zenshoen, Tokyo.

Nihon Rai Gakkai Zasshi
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment.

Pediatric dermatology·1992
Same author

Stimulation of keratinocyte migration by growth factors.

The Journal of dermatology·1992
Same author

A wound healing model using healing-impaired diabetic mice.

The Journal of dermatology·1992
Same author

The response to drug therapy in unstable angina on the basis of coronary angiography findings.

Japanese circulation journal·1992
Same author

[The pathogenic role of Chlamydia trachomatis in otitis media with effusion].

Nihon Jibiinkoka Gakkai kaiho·1992
Same author

[Prospective randomized trials comparing hyperfractionated radiotherapy with conventional radiotherapy in stage III non-small cell lung cancer].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same journal

The road to the abolition of the leprosy prevention law.

Nihon Rai Gakkai zasshi·1996
Same journal

[HLA class II alleles and leprosy (Hansen's disease) classified by WHO-MDT criteria].

Nihon Rai Gakkai zasshi·1996
Same journal

Establishment of mouse cell lines expressing Mycobacterium leprae 65 KDa heat shock protein gene.

Nihon Rai Gakkai zasshi·1996
Same journal

[BCG vaccination to Mycobacterium leprae infection in mice].

Nihon Rai Gakkai zasshi·1996
Same journal

A serologic Mycobacteria leprae gelatin particle agglutination (MLPA) in the diagnosis of leprosy: comparison with conventional enzyme-linked immunoassay and bacterial index.

Nihon Rai Gakkai zasshi·1996
Same journal

[Effects of glycerin and dextran on maintenance of the activity of Mycobacterium leprae in a cell-free liquid medium].

Nihon Rai Gakkai zasshi·1996
See all related articles

Incomplete leprosy treatment may lead to late-stage uveitis (UV), even years after bacterial negativity. Lower chemotherapy scores and higher antibodies indicate higher risk for this persistent ocular inflammation.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Immunology

Context:

  • Leprosy, a chronic infectious disease, can cause ocular complications like uveitis (UV) even after dermatological cure.
  • Late-phase uveitis in leprosy patients requires understanding risk factors for better management.
  • Patients studied were dermatologically cured, skin smear negative for over 10 years, but had ongoing uveitis.

Purpose:

  • To investigate the risk factors associated with late-phase uveitis in leprosy patients who are dermatologically cured.
  • To compare antibody levels and chemotherapy history between leprosy patients with and without uveitis.

Summary:

  • Anti-PGL-I and anti-LAM-B antibodies were elevated in leprosy patients with uveitis (UV+) compared to controls (UV-).
  • Patients with uveitis had a significantly lower chemotherapy "SCORE", indicating potentially insufficient treatment.

Related Experiment Videos

  • Iris pearls, a clinical sign of ocular inflammation, were observed in 42% of UV+ patients but none in controls.

    • Impact:

    • Findings suggest that insufficient chemotherapy and incomplete Mycobacterium leprae elimination are risk factors for developing uveitis in quiescent leprosy.
    • This highlights the importance of adequate treatment duration and monitoring for ocular complications in leprosy survivors.
    • Understanding these risk factors can guide preventative strategies and improve long-term patient outcomes.